Premium
Characterization of a small‐cell‐lung‐carcinoma cell line from a patient with cancer‐associated retinopathy
Author(s) -
Yamaji Yasufumi,
Matsubara Shuji,
Yamadori Ichiro,
Sato Makoto,
Fujita Toshikazu,
Fujita Jiro,
Takahara Jiro
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960301)65:5<671::aid-ijc18>3.0.co;2-a
Subject(s) - recoverin , biology , antibody , pathology , carcinoma , lung cancer , cell culture , microbiology and biotechnology , small cell carcinoma , cancer research , retinal , medicine , immunology , biochemistry , rhodopsin , genetics
We examined the biologic properties of a small‐cell‐lung‐carcinoma (SCLC) cell line (designated MN‐1112) established from a patient with SCLC who showed paraneoplastic retinopathy syndrome. Morphologic and immunocytochemical analyses showed that MN‐1112 cells possess features of the classic type of SCLC. MN‐1112 cells grew in suspension forming relatively large clumps of cells with a doubling time of 72 hr. By light‐microscope examination, the cells were relatively small and had scanty cytoplasm. The cells produced NSE, ACTH and CK (BB isozyme); they also expressed recoverin, a novel photoreceptor protein, detected by Northern‐blot and Western‐immunoblot analysis using human‐recoverin‐specific DNA probe and anti‐bovine‐recoverin polyclonal antibody. This report shows that human recoverin is expressed in cultured SCLC cells. Our results support the hypothesis that, in cancer‐associated retinopathy (CAR) patients, auto‐immune antibody targeting for ectopic recoverin in SCLC is initially produced and cross‐reacts with the retinal protein, resulting in the retinal degeneration that occurs in CAR patients. © 1996 Wiley‐Liss, Inc.